Education
About Us
Working with TipRanks
Follow Us
VolitionRX (VNRX)
:VNRX
VNRX Stock Chart & Stats
$0.29
$0.01(1.52%)
At close: 4:00 PM EST
$0.29
$0.01(1.52%)
Day’s Range― - ―
52-Week Range$0.22 - $0.94
Previous CloseN/A
Volume29.92K
Average Volume (3M)2.14M
Market Cap
$36.01M
Enterprise Value$83.20M
Total Cash (Recent Filing)$199.41K
Total Debt (Recent Filing)$11.26M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Mar 31, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding122,801,575
10 Day Avg. Volume2,474,334
30 Day Avg. Volume2,140,432
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-2.08
Price to Sales (P/S)42.09
P/FCF Ratio-1.96
Enterprise Value/Market Cap2.31
Enterprise Value/Revenue56.52
Enterprise Value/Gross Profit56.52
Enterprise Value/Ebitda-4.11
Forecast
1Y Price Target
$2.25Price Target Upside675.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.12
Revenue Forecast (FY)$8.71M
Bulls Say, Bears Say
Bulls Say
Clinical ValidationClinical evidence that the Nu.Q H3.1 biomarker outperforms established ICU severity scores supports adoption of the platform for critical-care diagnostics and strengthens clinical credibility.
Regulatory And Market AccessDirect sales of a CE-marked Nu.Q NETs assay and initial clinical certification sales for Nu.Q Cancer assays support a shift toward routine clinical use and broader revenue opportunities beyond veterinary products.
Strategic PartnershipsCommercial agreements with diagnostic firms, including a research license and a co-marketing arrangement with a major diagnostics company, open accelerated pathways to market for human-health assays.
Bears Say
Balance Sheet And Financing RiskLow cash reserves, high cash burn, and negative shareholders' equity create a financing overhang that may force dilutive capital raises and pressure the stock.
Conflict Of Interest And Report ObjectivityResearch providers' business relationships with covered companies raise potential conflicts of interest that could undermine perceived objectivity of analyst reports and investor confidence.
Revenue And Execution UncertaintyInconsistent revenue patterns and unclear timing and structure of partnership deals increase the risk that revenue will remain volatile and that growth targets may be missed.
VolitionRX News
VNRX FAQ
What was VolitionRX’s price range in the past 12 months?
VolitionRX lowest stock price was $0.22 and its highest was $0.94 in the past 12 months.
What is VolitionRX’s market cap?
VolitionRX’s market cap is $36.01M.
When is VolitionRX’s upcoming earnings report date?
VolitionRX’s upcoming earnings report date is Mar 31, 2026 which is in 71 days.
How were VolitionRX’s earnings last quarter?
VolitionRX released its earnings results on Nov 13, 2025. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.044 by -$0.006.
Is VolitionRX overvalued?
According to Wall Street analysts VolitionRX’s price is currently Undervalued.
Does VolitionRX pay dividends?
VolitionRX does not currently pay dividends.
What is VolitionRX’s EPS estimate?
VolitionRX’s EPS estimate is -0.04.
How many shares outstanding does VolitionRX have?
VolitionRX has 122,801,575 shares outstanding.
What happened to VolitionRX’s price movement after its last earnings report?
VolitionRX reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.044. Following the earnings report the stock price went down -6.497%.
Which hedge fund is a major shareholder of VolitionRX?
Currently, no hedge funds are holding shares in VNRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
VolitionRX Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.25 (675.86% Upside)
$2.25 (675.86% Upside)
Blogger Sentiment
Bullish
VNRX Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $7.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 5.5%
Last 30 Days ▲ 5.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-49.14%
Trailing 12-Months
Company Description
VolitionRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
VNRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in revenue growth, cost management, and strategic partnerships with major companies like Werfen and Hologic. Scientific advancements also promise future potential. However, challenges remain, such as unpredictable revenue and uncertainty in closing additional licensing agreements.View all VNRX earnings summariesVNRX Stock 12 Month Forecast
Average Price Target
$2.25
▲(675.86% Upside)
Technical Analysis
Ownership Overview
10.40% Insiders
1.37% Mutual Funds
0.20% Other Institutional Investors
87.20% Public Companies and
Individual Investors